Kennedy Capital Management
ADMA icon

Kennedy Capital Management’s ADMA Biologics ADMA Stock Holding History

Kennedy Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.7M Buy
1,755,152
+1,343,805
+327% +$12.3M 0.26% 127
2026
Q1 		$3.71M Sell
411,347
-266,253
-39% -$4.2M 0.08% 345
2025
Q4 		$12.4M Buy
677,600
+133,427
+25% +$2.25M 0.26% 140
2025
Q3 		$7.98M Buy
544,173
+117,137
+27% +$2.01M 0.18% 212
2025
Q2 		$7.78M Buy
427,036
+17,544
+4% +$358K 0.19% 204
2025
Q1 		$8.12M Buy
409,492
+139,840
+52% +$2.42M 0.19% 181
2024
Q4 		$4.62M Sell
269,652
-117,157
-30% -$2.2M 0.1% 342
2024
Q3 		$7.73M Sell
386,809
-44,324
-10% -$689K 0.17% 211
2024
Q2 		$4.82M Buy
431,133
+185,369
+75% +$1.56M 0.1% 333
2024
Q1 		$1.62M Sell
245,764
-288,411
-54% -$1.58M 0.03% 555
2023
Q4 		$2.41M Sell
534,175
-256,872
-32% -$950K 0.05% 453
2023
Q3 		$2.83M Sell
791,047
-318,038
-29% -$1.22M 0.07% 400
2023
Q2 		$4.09M Buy
1,109,085
+400,507
+57% +$1.48M 0.1% 333
2023
Q1 		$2.35M Sell
708,578
-1,540,893
-69% -$5.33M 0.07% 383
2022
Q4 		$8.73M Buy
+2,249,471
New +$6.94M 0.25% 134

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Kennedy Capital Management's ADMA Position: Q2 2026 in Review

Kennedy Capital Management increased its ADMA Biologics (ADMA) stake by 327% in Q2 2026, buying an estimated $12.3M and bringing the position to 1,755,152 shares worth $14.7M. The position accounts for 0.26% of the portfolio, ranked #127.

Kennedy Capital Management first reported a position in ADMA in Q4 2022 and has held it in 15 quarters since. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Kennedy Capital Management held 1,755,152 shares of ADMA Biologics worth $14.7M as of Q2 2026.
  • Kennedy Capital Management bought 1,343,805 ADMA Biologics shares in Q2 2026, an estimated $12.3M.
  • ADMA Biologics made up 0.26% of Kennedy Capital Management's portfolio in Q2 2026, its #127 holding.
  • Kennedy Capital Management first reported a position in ADMA Biologics in Q4 2022 and has held it in 15 quarters since.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.